HK1165791A1 - Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases - Google Patents

Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Info

Publication number
HK1165791A1
HK1165791A1 HK12106184.9A HK12106184A HK1165791A1 HK 1165791 A1 HK1165791 A1 HK 1165791A1 HK 12106184 A HK12106184 A HK 12106184A HK 1165791 A1 HK1165791 A1 HK 1165791A1
Authority
HK
Hong Kong
Prior art keywords
triazolopyridines
treatment
phosphodiesterase inhibitors
dermal diseases
dermal
Prior art date
Application number
HK12106184.9A
Other languages
English (en)
Chinese (zh)
Inventor
Simon Feldbk Nielsen
Thomas Vifian
Anne Marie Horneman
Jesper Frgemann Lau
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of HK1165791A1 publication Critical patent/HK1165791A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12106184.9A 2008-12-19 2012-06-25 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases HK1165791A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13944508P 2008-12-19 2008-12-19
PCT/DK2009/000262 WO2010069322A1 (en) 2008-12-19 2009-12-18 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Publications (1)

Publication Number Publication Date
HK1165791A1 true HK1165791A1 (en) 2012-10-12

Family

ID=41693461

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106184.9A HK1165791A1 (en) 2008-12-19 2012-06-25 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Country Status (25)

Country Link
US (1) US8952162B2 (es)
EP (1) EP2379548B1 (es)
JP (2) JP5743901B2 (es)
KR (1) KR20110094355A (es)
CN (1) CN102317287B (es)
AU (1) AU2009328752B2 (es)
BR (1) BRPI0922452A2 (es)
CA (1) CA2747022A1 (es)
CY (1) CY1117562T1 (es)
DK (1) DK2379548T3 (es)
ES (1) ES2570769T3 (es)
HK (1) HK1165791A1 (es)
HR (1) HRP20160488T1 (es)
HU (1) HUE027770T2 (es)
IL (1) IL213570A (es)
MX (1) MX2011006428A (es)
NO (1) NO20110871A1 (es)
NZ (1) NZ593595A (es)
PL (1) PL2379548T3 (es)
RS (1) RS54752B1 (es)
RU (1) RU2544011C2 (es)
SG (1) SG172206A1 (es)
SI (1) SI2379548T1 (es)
WO (1) WO2010069322A1 (es)
ZA (1) ZA201104422B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459258B (zh) 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
CA2768505C (en) 2009-07-17 2018-06-12 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
CN102781425B (zh) 2009-12-22 2014-08-13 利奥制药有限公司 含有维生素d类似物以及溶剂和表面活性剂混合物的皮肤用组合物
MX2012007225A (es) 2009-12-22 2012-07-30 Leo Pharma As Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
CA2785253A1 (en) 2009-12-22 2011-06-30 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
US9387195B2 (en) 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
MX2014006812A (es) * 2011-12-21 2014-10-13 Leo Pharma As [1,2,4] triazolopiridinas y su uso como inhibidores de fosfodiesterasa.
US9855285B2 (en) * 2012-11-30 2018-01-02 Leo Pharma A/S Method of inhibiting the expression of IL-22 in activated T-cells
WO2014206903A1 (en) 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
JP2020524131A (ja) 2017-06-20 2020-08-13 レオ ファーマ アクティーゼルスカブ １，３−ベンゾジオキソール複素環式化合物の調製方法
JP7203846B2 (ja) 2017-12-15 2023-01-13 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
AR114977A1 (es) * 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636086T2 (de) 1995-05-19 2006-11-30 Kyowa Hakko Kogyo Co., Ltd. Sauerstoff enthaltende heterocyclische verbindungen
EP0943613A4 (en) 1996-11-19 2002-07-10 Kyowa Hakko Kogyo Kk HETEROCYCLIC COMPOUNDS CONTAINING OXYGEN
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
US7763617B2 (en) 2005-03-07 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
JP2007091597A (ja) * 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤
US20090196284A1 (en) * 2006-06-28 2009-08-06 Nokia Siemens Networks Gmbh & Co.Kg Method for Providing an Emergency Call Service for VoIP Subscribers
AU2007272009A1 (en) * 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
JP2008024599A (ja) * 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬
JP2008069144A (ja) * 2006-08-17 2008-03-27 Kyorin Pharmaceut Co Ltd ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US8829190B2 (en) * 2007-04-16 2014-09-09 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
JPWO2008156102A1 (ja) 2007-06-19 2010-08-26 杏林製薬株式会社 ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US20100160335A1 (en) 2007-06-19 2010-06-24 Kyorin Pharmaceutical Co., Ltd. Pyridazinone derivative and pde inhibitor containing the same as active ingredient
JP2009040711A (ja) 2007-08-08 2009-02-26 Kyorin Pharmaceut Co Ltd カルボスティリル誘導体及びそれらを有効成分とするｐｄｅ阻害剤
EP2348018A4 (en) 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYLIC DERIVATIVE AND PDE INHIBITOR COMPRISING THE SAME AS ACTIVE INGREDIENT
JPWO2010041711A1 (ja) 2008-10-09 2012-03-08 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤

Also Published As

Publication number Publication date
US20120028974A1 (en) 2012-02-02
AU2009328752B2 (en) 2015-07-16
MX2011006428A (es) 2011-07-28
CN102317287B (zh) 2014-10-08
HUE027770T2 (en) 2016-11-28
JP2012512192A (ja) 2012-05-31
NO20110871A1 (no) 2011-09-19
IL213570A (en) 2015-10-29
EP2379548A1 (en) 2011-10-26
AU2009328752A1 (en) 2011-07-07
US8952162B2 (en) 2015-02-10
IL213570A0 (en) 2011-07-31
KR20110094355A (ko) 2011-08-23
WO2010069322A1 (en) 2010-06-24
RU2544011C2 (ru) 2015-03-10
PL2379548T3 (pl) 2016-08-31
ES2570769T3 (es) 2016-05-20
ZA201104422B (en) 2012-09-26
JP2015096535A (ja) 2015-05-21
NZ593595A (en) 2013-07-26
DK2379548T3 (en) 2016-05-17
HRP20160488T1 (hr) 2016-06-17
CA2747022A1 (en) 2010-06-24
CN102317287A (zh) 2012-01-11
EP2379548B1 (en) 2016-03-09
SI2379548T1 (sl) 2016-06-30
RS54752B1 (sr) 2016-10-31
JP5743901B2 (ja) 2015-07-01
SG172206A1 (en) 2011-07-28
BRPI0922452A2 (pt) 2015-12-15
CY1117562T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
HK1165791A1 (en) Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
HK1169804A1 (zh) 治療疼痛的方法
EP2259679A4 (en) METHOD FOR THE TREATMENT OF CALLIQUE CLEANING DISORDERS
HK1217763A1 (zh) 用於治療疾病的方法
HK1154575A1 (zh) 用於治療增生性疾病的不對稱吡咯並苯並二氮雜卓二聚物
IL208354A0 (en) Methods of treatment
AP2011005682A0 (en) Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases.
GB0902040D0 (en) Composition for treatment of skin
HK1176870A1 (zh) 疾病的治療方法
GB201010638D0 (en) Composition for treatment of skin
GB0805119D0 (en) Treatment of myelination diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181220